Mark FitzGerald, J.
Hamelmann, Eckard
Kerstjens, Huib A. M. http://orcid.org/0000-0001-7705-7927
Buhl, Roland
Funding for this research was provided by:
Boehringer Ingelheim (N/A, N/A, N/A)
Article History
Received: 4 October 2019
Accepted: 18 June 2020
First Online: 31 August 2020
Competing interests
: J.M.F. reports grants from Boehringer Ingelheim during the conduct of the study; personal fees and grants from Boehringer Ingelheim, AstraZeneca, Novartis, Sanofi-Regeneron, Circassia and Teva; and grants from GlaxoSmithKline outside the submitted work. E.H. has nothing to disclose. H.A.M.K. reports an unrestricted research grant, and fees for participation in advisory boards from Boehringer Ingelheim, Novartis and GlaxoSmithKline. He also reports fees for advisory board participation for AstraZeneca and Chiesi (all paid to his institution). R.B. has received grants and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche, and personal fees from AstraZeneca, Chiesi, Cipla and Teva.